<p>CG Oncology, Inc.（納斯達克股票代碼：CGON - 獲取免費報告）的股價週四下跌了 0.9%。股價最低下跌至 29.26 美元，最後交易價為 30.25 美元。交易中約有 408,077 股股票交易，較平均每日成交量 672,452 股下降了 39%。該股之前收盤價為 30.52 美元。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些股票研究分析師最近發佈了關於 CGON 股票的報告。高盛集團將 CG Oncology 的股票評級從 “中性” 調高至 “買入”，並在 5 月 13 日星期一的研究報告中將公司的價格目標從 43.00 美元上調至 50.00 美元。康泰菲茲（Cantor Fitzgerald）重申了對 CG Oncology 的 “超重” 評級，並在 5 月 2 日星期四的研究報告中設定了 75.00 美元的目標價。最後，HC Wainwright 重申了對 CG Oncology 的 “買入” 評級，並在 5 月 28 日星期二的報告中設定了 75.00 美元的價格目標。</p>
<p><strong>閲讀我們關於 CG Oncology 的最新報告</strong></p>
<h2>CG Oncology 股價下跌 0.9%</h2>
<p>該股票的五十日移動平均價格為 33.57 美元。</p>
<p>CG Oncology（納斯達克股票代碼：CGON - 獲取免費報告）最近發佈了其季度財報，日期為 5 月 9 日星期四。公司報告該季度每股收益（EPS）為-0.36 美元，低於預期的-0.35 美元。該季度公司的營收為 530 萬美元。分析師們預計，CG Oncology, Inc.今年將實現-1.71 美元的每股收益。</p>
<h2>對 CG Oncology 進行投資的對沖基金發表意見</h2>
<p>機構投資者和對沖基金最近對該股票的持倉進行了調整。Ameritas 投資合作伙伴公司在第一季度收購了 CG Oncology 的新頭寸，價值約 10.2 萬美元。加州州立教師退休金系統在第一季度收購了價值約 10.3 萬美元的 CG Oncology 新頭寸。法國巴黎銀行金融市場在第一季度收購了價值約 49.2 萬美元的 CG Oncology 新頭寸。Capstone 投資顧問有限責任公司在第一季度收購了價值約 80.6 萬美元的 CG Oncology 新頭寸。最後，Blackstone Inc.在第一季度收購了價值約 109.8 萬美元的 CG Oncology 新頭寸。26.56% 的股票由機構投資者和對沖基金持有。</p>
<h2>CG Oncology 公司簡介（獲取免費報告）</h2>
<p>CG Oncology, Inc.是一家腫瘤溶解免疫療法公司，專注於為膀胱癌患者開發和商業化骨幹膀胱保留治療方案。該公司開發了 BOND-003，用於治療高風險的卡介苗不敏感的非肌層侵襲性膀胱癌（NMIBC）患者；CORE-001 用於治療高風險的卡介苗不敏感的 NMIBC 患者，與 pembrolizumab 聯合使用；CORE-002 用於治療肌層侵襲性膀胱癌患者，與檢查點抑制劑 nivolumab 聯合使用。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 CG Oncology 更好</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>BlackBerry 股票：強勁的盈利，前方挑戰</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Progress Software 股票在超過預期後重回上漲</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>高盛集團為 Affirm 提高股價目標：關鍵見解</li>
</ul>
<p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 伊隆的下一個 IPO 可能比特斯拉還要大（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw"/></p>
<h2>您現在是否應該投資 1000 美元購買 CG Oncology 股票？</h2>
<p>在考慮 CG Oncology 之前，您可能希望聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 CG Oncology 並不在這份名單上。</p>
<p>儘管 CG Oncology 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CGON

<p>CG Oncology（納斯達克股票代碼：CGON）週四股價下跌了 0.9%，最低交易價為 29.26 美元。分析師已經設定了新的價格目標，機構投資者也對該股票的持倉進行了調整。CG Oncology 專注於開發和商業化針對膀胱癌患者的脊柱膀胱保留治療方案</p>

<p>CG Oncology, Inc. (NASDAQ:CGON - Get Free Report)'s stock price was down 0.9% on Thursday . The stock traded as low as $29.26 and last traded at $30.25. Approximately 408,077 shares were traded during trading, a decline of 39% from the average daily volume of 672,452 shares. The stock had previously closed at $30.52.</p>
<div class="lb-trans"><p>CG Oncology, Inc.（納斯達克股票代碼：CGON - 獲取免費報告）的股價週四下跌了 0.9%。股價最低下跌至 29.26 美元，最後交易價為 30.25 美元。交易中約有 408,077 股股票交易，較平均每日成交量 672,452 股下降了 39%。該股之前收盤價為 30.52 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of equities research analysts recently issued reports on CGON shares. The Goldman Sachs Group raised shares of CG Oncology from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price target for the company from $43.00 to $50.00 in a research note on Monday, May 13th. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and set a $75.00 price target on shares of CG Oncology in a report on Tuesday, May 28th.</p>
<div class="lb-trans"><p>一些股票研究分析師最近發佈了關於 CGON 股票的報告。高盛集團將 CG Oncology 的股票評級從 “中性” 調高至 “買入”，並在 5 月 13 日星期一的研究報告中將公司的價格目標從 43.00 美元上調至 50.00 美元。康泰菲茲（Cantor Fitzgerald）重申了對 CG Oncology 的 “超重” 評級，並在 5 月 2 日星期四的研究報告中設定了 75.00 美元的目標價。最後，HC Wainwright 重申了對 CG Oncology 的 “買入” 評級，並在 5 月 28 日星期二的報告中設定了 75.00 美元的價格目標。</p>
</div><p><strong>Read Our Latest Report on CG Oncology</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CG Oncology 的最新報告</strong></p>
</div><h2>CG Oncology Trading Down 0.9 %</h2>
<div class="lb-trans"><h2>CG Oncology 股價下跌 0.9%</h2>
</div><p>The stock's fifty day moving average price is $33.57.</p>
<div class="lb-trans"><p>該股票的五十日移動平均價格為 33.57 美元。</p>
</div><p>CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $0.53 million for the quarter. As a group, analysts forecast that CG Oncology, Inc. will post -1.71 EPS for the current year.</p>
<div class="lb-trans"><p>CG Oncology（納斯達克股票代碼：CGON - 獲取免費報告）最近發佈了其季度財報，日期為 5 月 9 日星期四。公司報告該季度每股收益（EPS）為-0.36 美元，低於預期的-0.35 美元。該季度公司的營收為 530 萬美元。分析師們預計，CG Oncology, Inc.今年將實現-1.71 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On CG Oncology</h2>
<div class="lb-trans"><h2>對 CG Oncology 進行投資的對沖基金發表意見</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of CG Oncology during the first quarter worth about $102,000. California State Teachers Retirement System acquired a new position in CG Oncology in the first quarter valued at approximately $103,000. BNP Paribas Financial Markets acquired a new position in CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC acquired a new position in CG Oncology in the first quarter valued at approximately $806,000. Finally, Blackstone Inc. acquired a new position in CG Oncology in the first quarter valued at approximately $1,098,000. 26.56% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該股票的持倉進行了調整。Ameritas 投資合作伙伴公司在第一季度收購了 CG Oncology 的新頭寸，價值約 10.2 萬美元。加州州立教師退休金系統在第一季度收購了價值約 10.3 萬美元的 CG Oncology 新頭寸。法國巴黎銀行金融市場在第一季度收購了價值約 49.2 萬美元的 CG Oncology 新頭寸。Capstone 投資顧問有限責任公司在第一季度收購了價值約 80.6 萬美元的 CG Oncology 新頭寸。最後，Blackstone Inc.在第一季度收購了價值約 109.8 萬美元的 CG Oncology 新頭寸。26.56% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>CG Oncology Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>CG Oncology 公司簡介（獲取免費報告）</h2>
</div><p>CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.</p>
<div class="lb-trans"><p>CG Oncology, Inc.是一家腫瘤溶解免疫療法公司，專注於為膀胱癌患者開發和商業化骨幹膀胱保留治療方案。該公司開發了 BOND-003，用於治療高風險的卡介苗不敏感的非肌層侵襲性膀胱癌（NMIBC）患者；CORE-001 用於治療高風險的卡介苗不敏感的 NMIBC 患者，與 pembrolizumab 聯合使用；CORE-002 用於治療肌層侵襲性膀胱癌患者，與檢查點抑制劑 nivolumab 聯合使用。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than CG Oncology</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Progress Software Stock Back in the Green After Beating Forecasts</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Goldman Sachs Raises Stock Target for Affirm: Key Insights</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 CG Oncology 更好</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>BlackBerry 股票：強勁的盈利，前方挑戰</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Progress Software 股票在超過預期後重回上漲</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>高盛集團為 Affirm 提高股價目標：關鍵見解</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 伊隆的下一個 IPO 可能比特斯拉還要大（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8510&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in CG Oncology right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1000 美元購買 CG Oncology 股票？</h2>
</div><p>Before you consider CG Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CG Oncology 之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 CG Oncology 並不在這份名單上。</p>
</div><p>While CG Oncology currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 CG Oncology 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

CG Oncology（納斯達克代碼：CGON）股價下跌 0.9%